Floatz logo

Lapatinib

Neoplasm Metastasis

University of Maryland, BaltimoreSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
73/ 100

Competitive context

171 Active assets in the Neoplasm Metastasis cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Lapatinib is also rated in:

breast cancerDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
male breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →